Bajaj Healthcare Q3 PAT up 34% YoY to Rs 1,567 lakhs; revenue rises 31%

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

BAJAJHCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.7%Reaction day

₹388.00

prior close

₹392.40

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.7%-2.0% vs market

Pharmaceuticals peers, median of 157sector-2.1%-2.6% vs sector

On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 2.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.5

10m

-1.9

15m

-2.3

30m

-1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.7-2.7-2.0-2.1-2.6

Next day

-6.6-3.5-3.2-3.4-3.3

-7.5-2.0-5.5-2.0-5.5

-10.3-4.1-6.3-3.2-7.1

-13.7-3.9-9.8-3.5-10.2

-11.1-2.0-9.1-3.2-7.9

-10.5-0.6-9.9-2.2-8.3

15d

-3.6+4.4-8.1+1.1-4.8

-9.7+1.3-11.0-1.5-8.2

-20.1-6.9-13.2-7.9-12.2

-14.4+4.6-19.0-0.1-14.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bajaj Healthcare reported Q3 FY26 revenue from operations of Rs 16,122 lakhs, up 31% from Rs 12,279 lakhs a year ago. Profit after tax (total) rose 34% to Rs 1,567 lakhs versus Rs 1,172 lakhs. For the nine months ended December 2025, total PAT grew 36% to Rs 3,862 lakhs. Statutory auditor Walker Chandiok issued an unmodified limited review. The Board also reappointed the Chairman and Managing Director and three executive directors for three-year terms and approved a postal ballot to seek shareholder approval.

Likely market impact

Strong YoY revenue and profit growth; continuity at top leadership through director reappointments, subject to shareholder vote.